Skip to main content
Journal of Patient-Reported Outcomes

Table 3 Baseline demographics and patients’ clinical characteristics of n = 79 women with breast cancer

From: Cancer treatment regimens and their impact on the patient-reported outcome measures health-related quality of life and perceived cognitive function

Variable

Group SC

Group SCR

Group SR

Group S

N. (%)

22 (100.0)

17 (100.0)

27 (100.0)

13 (100.0)

Age [years]

51.9 ± 11.6

54.4 ± 8.5

56.7 ± 9.0

55.3 ± 7.3

p

0.30

0.21

0.06

0.28

Age, 30–35 years n (%)

2 (9.1)

0 (0.0)

0 (0.0)

0 (0.0)

Age, 35–40 years n (%)

2 (9.1)

0 (0.0)

3 (11.1)

0 (0.0)

Age, 41–49 years n (%)

5 (22.7)

6 (45.5)

2 (7.4)

3 (23.1)

Age, 50–59 years n (%)

6 (27.3)

4 (23.5)

9 (33.3)

6 (46.2)

Age, 60–69 years n (%)

7 (31.8)

7 (41.2)

13 (48.2)

4 (30.8)

Height [m]

1.65 ± 0.08

1.65 ± 0.08

1.61 ± 0.06

1.63 ± 0.08

p

0.43

0.77

0.56

0.24

Weight [kg]

72.1 ± 14.2

82.7 ± 20.2

68.6 ± 12.4

72.6 ± 12.5

p

0.29

0.11

0.66

0.55

BMI [kg m−2]

26.4 ± 5.0

30.5 ± 6.8

26.4 ± 4.8

27.4 ± 4.3

p

0.08

0.08

0.48

0.17

UICC n (%)

IA: 5 (22.7)

IIA:10 (45.5) IIIA: 1 (4.6)

IIB: 6 (27.3)

IA: 7 (41.2)

IIA:7 (41.2)

IB: 2 (11.8)

IIB: 1 (5.9)

IA: 25 (92.6)

IIA: 2 (7.4)

IB: 0 (0.0)

IIB: 0 (0.0)

IA: 5 (38.5)

IIA: 8 (61.5)

IB: 0 (0.0)

IIB: 0 (0.0)

TT (month)

7.7 ± 1.3

10.4 ± 1.6

5.3 ± 1.5

2.5 ± 1.6

Her2/neu status,

n (%)

Pos. 1 (4.5)

Neg. 21 (94.5)

Pos. 2 (11.8)

Neg. 15 (88.2)

Pos. 0 (0.0)

Neg. 27 (100.0)

Pos. 13 (100.0)

Neg. 0 (0.0)

ER status,

n (%)

Pos. 13 (59.1)

Neg. 9 (40.9)

Pos. 14 (82.4)

Neg. 3 (17.7)

Pos. 27 (100.0)

Neg. 0 (0.0)

Pos. 13 (100.0)

Neg. 0 (0.0)

MC, n (%)

1 (4.6)

1 (5.9)

0 (0.0)

0 (0.0)

IDC, n (%)

18 (81.8)

16 (94.1)

24 (88.9)

7 (53.9)

IDC-L, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

1 (7.7)

ILC, n (%)

3 (13.6)

0 (0.0)

2 (7.4)

5 (38.5)

ICC, n (%)

0 (0.0)

0 (0.0)

1 (3.7)

0 (0.0)

SNB, n (%)

21 (95.5)

15 (88.2)

27 (100.0)

13 (100.0)

ALND, n (%)

5 (22.7)

3 (17.7)

0 (0.0)

0 (0.0)

BCS, n (%)

8 (36.4)

16 (94.1)

27 (100.0)

0 (0.0)

MRM, n (%)

2 (9.1)

1 (5.9)

0 (0.0)

2 (15.4)

SCM, n (%)

9 (40.9)

0 (0.0)

0 (0.0)

10 (76.9)

BCS + SCM, n (%)

3 (13.6)

0 (0.0)

0 (0.0)

1 (7.7)

TMX, n (%)

1 (4.5)

4 (23.5)

6 (22.2)

1 (7.7)

ALs, n (%)

13 (59.1)

9 (52.9)

20 (74.1)

11 (84.6)

Neoadjuvant C, n (%)

10 (45.5)

9 (52.9)

0 (0.0)

0 (0.0)

Adjuvant C, n (%)

13 (59.1)

8 (47.1)

0 (0.0)

0 (0.0)

Anth-bCTx, n (%)

12 (54.6)

9 (52.9)

0 (0.0)

0 (0.0)

TaxAnth-C, n (%)

10 (45.5)

8 (47.1)

0 (0.0)

0 (0.0)

R, n (%)

0 (0.0)

17 (100.0)

27 (100.0)

0 (0.0)

  1. Means ± standard deviation (SD); n = number of patients (%); normally distribution (Shapiro–Wilk test) p > 0.05; SCR, Surgery + Chemotherapy + Radiotherapy; SC; SR; S; ALND, Axillary lymph node dissection; ALs, Aromatase inhibitors; Anth-bC, Anthracycline-Based Chemotherapy; BCS, Breast-conserving surgery; ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2; ICC, invasive cribriform carcinoma; IDC, Invasive ductal carcinoma; IDC-L, invasive ductal carcinoma with lobular features; ILC, invasive lobular carcinoma; MC, Mucinous breast carcinoma; MRM, Modified Radical Mastectomy; R, Radiotherapy; SCM, Subcutaneous mastectomy; SNB, Sentinel node biopsy; TMX, Tamoxifen; TaxAnth-C, Anthracycline-Taxane-Based Chemotherapy; TT, Time of Treatment; UICC, Union for International Cancer Control
Back to article page